Given the role of VEGFA in NAFLD pathogenesis, the reduction in this angiogenic factor by tesamorelin may in part underlie its attenuation of NAFLD progression in HIV. This evidence concerns the gene VEGFA and metabolic dysfunction-associated steatotic liver disease.